The Justice Department recently announced that Ahold Delhaize USA Inc., which operates supermarket pharmacies under banners including Stop & Shop, Giant, Hannaford, and Food Lion, agreed to pay the United States and participating states $40 million to resolve allegations that it violated the False Claims Act and state analogues by reporting inflated prescription-drug prices to government health programs. DOJ announced the settlement on June 10, 2026.
The alleged issue was not that the pharmacies failed to dispense the drugs. It was pricing. According to DOJ, Ahold Delhaize pharmacies operated prescription savings programs that offered discounted prices to enrolled customers. DOJ alleged those discounted prices should have been reported as the pharmacies’ “usual and customary” prices on claims submitted to Medicare Part D, Medicaid, and TRICARE. Instead, the government contended, the pharmacies reported higher pre-discount prices, causing federal health programs to reimburse more than they should have.
That distinction matters because “usual and customary” prices often operate as ceiling prices in government reimbursement formulas. When a pharmacy’s true cash or discount price is lower than the amount reported to a government payer, the reimbursement claim may be inflated and thus “false,” even though the prescription itself was real.
The case highlights why pharmacy insiders can be important healthcare fraud whistleblowers. The civil settlement resolves a qui tam lawsuit filed by Lawrence LaBenne, a pharmacist who worked at an Ahold Delhaize supermarket in Pennsylvania. LaBenne will receive more than $6 million from the federal share of the settlement.
For would-be whistleblowers, the takeaway is practical: billing fraud can be hidden in price fields, reimbursement logic, and program-specific definitions, not only in whether a service was provided. Pharmacists, pharm techs, PBM employees, reimbursement specialists, and compliance staff may see whether discount programs are being included in—or excluded from—government-price reporting. If the discount is real to the customer but invisible to Medicare, Medicaid, or TRICARE, that mismatch may deserve legal review. DOJ’s action underscores a recurring FCA theme: when companies participate in taxpayer-funded health programs, pricing representations can be just as important as clinical representations.
